• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Beyond Air, Inc. Urges Stockholders to Vote "FOR" All Proposals Ahead of the Upcoming Special Meeting

    6/10/26 8:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care
    Get the next $XAIR alert in real time by email

    Special Meeting of Stockholders Scheduled for June 18, 2026 at 4:30 p.m. Eastern Time

    Proxies have been mailed to stockholders of record as of the close of business on April 20, 2026; contact information is included below to request additional copies

    GARDEN CITY, N.Y., June 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company") today reminded stockholders of record to submit their votes ahead of the Company's upcoming Special Meeting of Stockholders (the "Special Meeting"), scheduled for Thursday, June 18, 2026 at 4:30 p.m. Eastern Time. The Special Meeting will be held in person at the Company's offices located at 900 Stewart Avenue, Suite 301, Garden City, New York, 11530.

    The Board of Directors of Beyond Air unanimously recommends that stockholders vote "FOR" all proposals at the Special Meeting. YOUR VOTE IS IMPORTANT, regardless of the number of shares you own.

    Why This Vote Is Critical

    On April 7, 2026, Beyond Air received a written notification from the Nasdaq Listing Qualifications Department stating that the Company no longer satisfies the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market, based on the closing bid price of its Common Stock for 30 consecutive business days. As a result, Beyond Air's Common Stock is at risk of being delisted from Nasdaq unless the Company takes corrective action.

    The approval of Proposal 1 would authorize the Board to effect a reverse stock split at a ratio ranging from 1-for-2 to 1-for-20, which the Board believes is necessary to increase the per share price of Beyond Air's Common Stock above the $1.00 minimum threshold required for continued Nasdaq listing. If this proposal does not pass, the Company expects that its Common Stock will be subject to delisting proceedings from Nasdaq.

    Maintaining the Company's Nasdaq listing is critically important for the following reasons:

    • Continued access to capital markets, which is essential for Beyond Air to fund its ongoing clinical development programs and operations.
    • Preservation of liquidity for stockholders, as delisted stocks trade less frequently and in smaller volumes, making it harder to buy or sell shares.
    • Investor eligibility requirements, as many institutional investors are prohibited from holding stocks that are not listed on a national securities exchange.
    • Delisting could trigger an obligation to seek an in-court or out-of-court restructuring of the Company's liabilities, which would likely result in a total loss of investment for holders of Common Stock.

    Statement from CEO Robert Goodman

    "Approving the reverse stock split is a necessary and important step to protect the long-term interests of our stockholders and preserve Beyond Air's ability to remain listed on Nasdaq. Maintaining our listing is fundamental to our ability to access the capital markets, continue advancing our pipeline, and deliver on our mission of developing transformative therapies for patients. We urge all stockholders to make their voices heard by voting FOR all proposals before the June 18th deadline. Every vote counts and we appreciate the continued support of our stockholders."

    Robert Goodman, Chief Executive Officer, Beyond Air, Inc.

    Proposals to Be Voted Upon

    Proposal 1 — Reverse Stock Split: To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to authorize the Board, at its discretion, to effect a reverse stock split of the Company's issued and outstanding shares of Common Stock at a ratio ranging from 1-for-2 to 1-for-20, with the exact ratio to be determined by the Board.

    Proposal 2 — Adjournment Proposal: To approve a proposal to adjourn the Special Meeting to a later date, if necessary, to permit further solicitation of proxies in the event that there are insufficient votes to approve Proposal 1.

    Questions or Voting Assistance

    If you have any questions about the Special Meeting, require assistance voting your shares, or need additional copies of proxy materials, please contact Beyond Air's proxy solicitor:

    Laurel Hill Advisory Group

    Stockholders may call toll-free:

    888.742.1305

    Direct/International: 516.933.3100

    Email: jdepinto@laurelhill.com

    Stockholders of record as of the close of business on April 20, 2026 (the "Record Date") are entitled to vote. The deadline for voting by Internet or telephone is 11:59 p.m. Eastern Time on June 17, 2026. Stockholders may vote their shares by:

    • By Internet: Visit www.proxyvote.com prior to 11:59 p.m. Eastern Time on June 17, 2026.
    • By Telephone: Call toll-free 1-800-690-6903 prior to 11:59 p.m. Eastern Time on June 17, 2026.
    • By Mail: Complete, sign, date and return the proxy card in the postage-paid envelope provided.
    • In Person: Attend and vote at the Special Meeting on June 18, 2026 at 900 Stewart Avenue, Suite 301, Garden City, NY 11530.



    THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE "FOR" PROPOSALS 1 AND 2.
     
    Failure to vote FOR the Reverse Stock Split Proposal may result in the delisting of XAIR from the Nasdaq Capital Market.



    About Beyond Air, Inc.

    Beyond Air, Inc. (NASDAQ:XAIR) is a clinical-stage biopharmaceutical and medical device company developing nitric oxide (NO) generators and delivery systems for the treatment of respiratory conditions and various other indications. Beyond Air's platform utilizes NO generated from ambient air to treat patients suffering from respiratory illnesses and is the foundation for treating a wide range of medical conditions.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, including statements regarding the Special Meeting, the proposed reverse stock split and continued Nasdaq listing. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expected. Beyond Air does not undertake any obligation to publicly update or revise any forward-looking statement, except as required by law.

    Additional Information and Where to Find It

    Beyond Air has filed a definitive proxy statement and other relevant documents with the U.S. Securities and Exchange Commission (the "SEC") in connection with the Special Meeting. Stockholders are urged to read the proxy statement carefully and in its entirety. The proxy statement and other relevant documents can be obtained free of charge at the SEC's website at www.sec.gov or at www.proxyvote.com.

    Investor Contact:

    Beyond Air, Inc.

    900 Stewart Avenue, Suite 301 | Garden City, NY 11530

    Tel: (516) 665-8200



    Primary Logo

    Get the next $XAIR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XAIR

    DatePrice TargetRatingAnalyst
    7/17/2025$11.00Buy
    D. Boral Capital
    6/25/2024Buy → Neutral
    BTIG Research
    7/28/2023$10.00Overweight
    Piper Sandler
    6/15/2023$15.00Buy
    BTIG Research
    11/12/2021$12.00 → $16.00Buy
    Truist Securities
    More analyst ratings

    $XAIR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman of the Board Lisi Steven A. bought $19,491 worth of shares (6,000 units at $3.25), increasing direct ownership by 0.18% to 3,327,411 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    7/23/25 4:05:39 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Director Carey Robert bought $250,050 worth of shares (1,000,000 units at $0.25), increasing direct ownership by 33% to 4,076,864 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    3/17/25 8:15:33 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Gaul Michael A. bought $2,294 worth of shares (6,000 units at $0.38), increasing direct ownership by 7% to 94,150 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    2/21/25 5:00:14 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Moorhead Daniel J

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    1/6/26 4:17:51 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Moorhead Daniel J

    3 - Beyond Air, Inc. (0001641631) (Issuer)

    1/6/26 4:15:38 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Lee Yoori

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    11/24/25 5:22:10 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital initiated coverage on Beyond Air with a new price target

    D. Boral Capital initiated coverage of Beyond Air with a rating of Buy and set a new price target of $11.00

    7/17/25 8:02:31 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air downgraded by BTIG Research

    BTIG Research downgraded Beyond Air from Buy to Neutral

    6/25/24 8:04:46 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Piper Sandler initiated coverage on Beyond Air with a new price target

    Piper Sandler initiated coverage of Beyond Air with a rating of Overweight and set a new price target of $10.00

    7/28/23 7:37:57 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast

    GARDEN CITY, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that it will report financial results for its fiscal fourth quarter and full year ended March 31, 2026 on Friday, June 26, 2026. The Company's management team is scheduled to host a conference call and webcast at 8:00 am Eastern Time (ET) the same day. Conference Call & WebcastFriday, June 26th @ 8:00 a.m. ETDomestic:1-877-407-0784International:1-201-689-8560Conference ID:13761239 Webcast: A webcast of the live confe

    6/22/26 4:01:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air, Inc. Urges Stockholders to Vote "FOR" All Proposals Ahead of the Upcoming Special Meeting

    Special Meeting of Stockholders Scheduled for June 18, 2026 at 4:30 p.m. Eastern Time Proxies have been mailed to stockholders of record as of the close of business on April 20, 2026; contact information is included below to request additional copies GARDEN CITY, N.Y., June 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company") today reminded stockholders of record to submit their votes ahead of the Company's upcoming Special Meeting of Stockholders (the "Special Meeting"), scheduled for Thursday, June 18, 2026 at 4:30 p.m. Eastern Time. The Special Meeting will be held in person at the Company's offices located at 900 Stewart Avenue, Suite 30

    6/10/26 8:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing

    GARDEN CITY, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request to continue its listing on The Nasdaq Stock Market, subject to regaining compliance with the Nasdaq Stock Market LLC's ("Nasdaq" or the "Exchange") Listing Rule 5550(a)(2) (the "Bid Price Rule") by July 31, 2026. The Company is fully compliant with all other continued listing requirements. "We appreciate the Panel's thoughtful review and support of our compliance plan,"

    6/1/26 8:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    SEC Filings

    View All

    Beyond Air Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events

    8-K - Beyond Air, Inc. (0001641631) (Filer)

    6/22/26 4:15:30 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air Inc. filed SEC Form 8-K: Other Events

    8-K - Beyond Air, Inc. (0001641631) (Filer)

    6/1/26 4:30:41 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Beyond Air Inc.

    SCHEDULE 13G/A - Beyond Air, Inc. (0001641631) (Subject)

    5/15/26 4:51:59 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 1, 2022 - FDA Roundup: July 1, 2022

    For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

    7/1/22 11:54:25 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Beyond Air Inc.

    SC 13G/A - Beyond Air, Inc. (0001641631) (Subject)

    10/9/24 1:35:29 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Beyond Air Inc.

    SC 13G - Beyond Air, Inc. (0001641631) (Subject)

    10/3/24 3:09:56 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Beyond Air Inc.

    SC 13G - Beyond Air, Inc. (0001641631) (Subject)

    3/7/24 12:29:51 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Financials

    Live finance-specific insights

    View All

    Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast

    GARDEN CITY, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that it will report financial results for its fiscal fourth quarter and full year ended March 31, 2026 on Friday, June 26, 2026. The Company's management team is scheduled to host a conference call and webcast at 8:00 am Eastern Time (ET) the same day. Conference Call & WebcastFriday, June 26th @ 8:00 a.m. ETDomestic:1-877-407-0784International:1-201-689-8560Conference ID:13761239 Webcast: A webcast of the live confe

    6/22/26 4:01:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast

    GARDEN CITY, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the second quarter of its fiscal year 2025 ended September 30, 2024 on Monday, November 11, 2024 after the market closes. Conference Call & WebcastMonday, November 11th @ 4:30 PM ETDomestic: 1-877-407-0784International: 1-201-689-8560Conference ID: 13749670Webcast: A webcast of the live conference call can be accessed by visiting the Eve

    10/29/24 4:22:08 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022

    LungFit® PH received FDA approval for the treatment of term and near-term neonates with hypoxic respiratory failure on June 28, 2022 and the first phase of U.S. commercial launch has begun Presented positive data for high-concentration nitric oxide (NO) with LungFit® PRO in hospitalized patients with community-acquired viral pneumonia, including COVID-19, at ECCMID 2022 Presented positive long-term safety data for high-concentration NO at PAS 2022 in infants hospitalized with bronchiolitis Presented positive updated interim data from the ongoing at-home LungFit® GO pilot study for nontuberculous mycobacterial lung disease at ATS 2022 Patient screening has begun for the Phase I trial of

    6/28/22 4:10:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Leadership Updates

    Live Leadership Updates

    View All

    Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO

    GARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi has resigned as Chief Executive Officer and stepped down from the Board of Directors, effective March 27, 2026, to pursue other opportunities. The Board of Directors has appointed Robert Goodman, the Company's current Chief Commercial Officer and Director, as Chief Executive Officer, effective today. For the past nine years, Mr. Lisi has led Beyond Air, guiding the development and launch of th

    3/26/26 4:05:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Cancer™ Announces the Appointment of Jedidiah Monson, M.D. to Chief Medical Officer

    Dr. Monson is a board-certified radiation oncologist and brings over 25 years of clinical oncology experience to Beyond Cancer. Dr. Monson is a founding partner and President of California Cancer Associates for Research & Excellence (cCARE), the largest private oncology practice in California. HAMILTON, Bermuda, June 01, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ:XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Jedidiah Monson, M.D. to the position of Chief Medical Officer, effective June 1, 2022. "We are excited to appoint Dr. Monson as

    6/1/22 7:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Cancer, Ltd. Appoints Susan Howell Jones, CPA as Chief Financial Officer

    HAMILTON, Bermuda, May 17, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ:XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Susan Howell Jones, CPA as Chief Financial Officer. Ms. Jones joins Beyond Cancer™ with over 30 years of international and operational financial leadership experience, including 20 years within the bioscience sector of BASF, a globally recognized chemical company. In her role as Senior Manager of Operational Accounting she was a key member of the implementation team responsible for the $4B acquisition of American Cyanamid. Follow

    5/17/22 7:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care